The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy

Trial Profile

The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms REBBeCA-II
  • Most Recent Events

    • 06 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 06 Oct 2013 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met.
    • 06 Oct 2013 Primary endpoint 'Hip-bone-mineral-density' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top